Literature DB >> 18365340

Substantial immune suppression required in gene therapy for muscular dystrophy?

Roland W Herzog1, Valder R Arruda.   

Abstract

Entities:  

Mesh:

Year:  2008        PMID: 18365340     DOI: 10.1016/j.nmd.2007.08.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


× No keyword cloud information.
  2 in total

1.  Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B.

Authors:  Ou Cao; Brad E Hoffman; Babak Moghimi; Sushrusha Nayak; Mario Cooper; Shangzhen Zhou; Hildegund C J Ertl; Katherine A High; Roland W Herzog
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

2.  Muscular dystrophy therapy by nonautologous mesenchymal stem cells: muscle regeneration without immunosuppression and inflammation.

Authors:  Arsalan Shabbir; David Zisa; Merced Leiker; Curtis Johnston; Huey Lin; Techung Lee
Journal:  Transplantation       Date:  2009-05-15       Impact factor: 4.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.